1. Ludwig H, Birgregard G, Olmi P, Nortier J. European Cancer Anaemia Survey (ECAS): prospective evaluation of anemia in over 15,000 cancer (CA) patients (pts). Ann Oncol 2002; 13 (Suppl. 5): 169 (A623PD).
2. Ludwig H. Epoetin in cancer-related anemia. Nephol Dail Transplant 1999; Suppl.
3. Groopman JE, Itri L.M. Chemotherapy-induced anemia in adults:incidence and treatment J NatlCancer Inst 1999; 6 91(19): 1616–34.
4. Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anemia. Dis Manage Health Outcomes 2000 Nov; 8 (5): 259–72.
5. Thomas ML. Impact of anemia and fatigue on qulity of life in cancer patients: brief rewiew. Med Oncol 1998 Aug; 15 (Supl. 1): S3–7.
6. H_ckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28 (Suppl. 8): 36–4.
7. Von Hoff DD, Schilsky R, Reichert CM et al. Toxic effects of cisdichlorodiammineplatinum (II) in man, Cancer Treat Rep 1979; 63: 1527–31.
8. Miller СВ. Chemotherapy-induced anemia. In Gurland HG, Moran J, Samtleben W, Scigalla P, Wieczorek L (eds): Erythropoietin in Renal and Non-Renal Amenias. Contrib Nephrol. Basel: Karger 1991; 88: 248–51.
9. Wood PA, Hrushesky JM. Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest 1995; 95: 1650–9.
10. Ten Bokkel, Huinink WW. Controlled multicenter study of the influence of two different dosages of subcutaneous rhEPO on the development of anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based combination chemotherapy. In Smyth JF, Boogaerts MA, Ehmer BR-M (eds): rhErythropoietin in Cancer Supportive Treatment. New York: Marcel Dekker, Inc. 1996; 99–112.
11. Ludwig et al. Eur J Cancer 2004; 40: 2293–306.
12. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378–81.
13. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, II: 1986; 1175–8.
14. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73–8.
15. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A (Suppl. 2): S2–8.
16. Oberhoff C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemo-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9: 255–60.
17. ten Bokkel Huinink WW, de swart CAM, van Torn DW et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 174–82.
18. Zache P. Controveries in selection of epoetin dosages; issues and answers. Drugs 1995; 49 (4): 536–47.
19. Johansoon J-E, Wersal P et al. Efficacy of epoetin beta on hemoglobin, quliaty of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer. Scand J Uron Nephrol 2001; 35: 288–94.
20. 20 Olsson A-M, Svensson J-H et al. Erythropoetin treatment in metastatic breast cancer: effects on Hb, quliaty of life and need of transfusion. Acta Oncol 2002; 41 (6): 517–24.
21. Tsukuda M, Yuyama S et al. Effectiveness of weekly subcutaneous recombinant human erythropoietin admistration for chemotherapy-induced anemia. Biotherapy 1998; 11 (1): 21–5.
22. Chan S, Reed N, Hayward C et al. Wim ten Bokkel Huinink.Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy. J Clin Oncol 2005; 23 (Suppl. 16):: 479, Abstract P-5102.
23. De Mastro L, Venturini M, Rosso R. Randomized phase III trial evaluating the role of erythropoetin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15: 2715–21.
24. Krantz S.B Erythropoetin. Blood 1991 Feb 1; 77 (3): 419–34.
25. Boogaerts M, Coiffier B et al. Impact of epoetin-b on quliaty of life in patients with malignant disease. Br J Can 2003; 88: 988–95.